Format

Send to

Choose Destination
Sci Rep. 2018 Sep 11;8(1):13586. doi: 10.1038/s41598-018-31783-x.

Ghrelin expression is associated with a favorable outcome in male breast cancer.

Author information

1
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. malin.gronberg@medsci.uu.se.
2
Center for Clinical Research, Västmanland County Hospital, Västerås, Sweden.
3
Division of Oncology and Pathology, Department of Clinical Sciences, and CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden.
4
Department of Oncology, Helsinki University, Helsinki, Finland.
5
Department of Oncology, Örebro University Hospital, Örebro, Sweden.
6
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
7
Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
8
Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden.

Abstract

Ghrelin and obestatin are two gastrointestinal peptides, derived from a common precursor. Expression of both peptides have been found in breast cancer tissue and ghrelin has been associated with breast cancer development. Ghrelin expression is associated with longer survival in women diagnosed with invasive and node negative breast cancer. The clinical implications of the peptide expression in male breast cancer are unclear. The aim of this study was to investigate the role and potential clinical value of ghrelin and obestatin in male breast cancer. A tissue microarray of invasive male breast cancer specimens from 197 patients was immunostained with antibodies versus the two peptides. The expression of the peptides was correlated to previously known prognostic factors in breast cancer and to the outcome. No strong correlations were found between ghrelin or obestatin expression and other known prognostic factors. Only ghrelin expression was statistically significantly correlated to breast cancer-specific survival (HR 0.39, 95% CI 0.18-0.83) in univariate analyses and in multivariate models, adjusted for tumor size and node status (HR 0.38, 95% CI 0.17-0.87). HR for obestatin was 0.38 (95% CI 0.11-1.24). Ghrelin is a potential prognostic factor for breast cancer death in male breast cancer. Patients with tumors expressing ghrelin have a 2.5-fold lower risk for breast cancer death than those lacking ghrelin expression. Drugs targeting ghrelin are currently being investigated in clinical studies treating metabolic or nutritional disorders. Ghrelin should be further evaluated in forthcoming studies as a prognostic marker with the aim to be included in decision algorithms.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center